Evaluation of the efficacy, safety and injection interval of intravitreal injection of ranibizumab for retinal vein occlusio
Not Applicable
- Conditions
- retinal vein occlusion
- Registration Number
- JPRN-UMIN000012038
- Lead Sponsor
- Department of Ophthalmology, Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
severe renal disease unstable angina malignant arrhythmia history of brain infarction history of cerebral hemorrhage severe hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variation on a logarithm of the minimum angle of resolution at 12 months after the first intravitreal injection
- Secondary Outcome Measures
Name Time Method The rate of complication at 12 months after the first intravitreal injection Variation on a central retinal thickness